Feed ADTX
AD

Aditxt, Inc.

ADTX · OTC

$0.00 +4.44% (+$0.00)
1M -20.69%
Market Cap $4.57M
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$0.01

112.8% upside

Current Price

$0.0047

Undervalued Fair Value Overvalued

According to Bulios Fair Price, ADTX is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 318.48x
EV/EBITDA N/A
P/B N/A
Growth
8 /100
Declining
Book val. growth 2.52%
Rev. growth 84.93%
FCF growth N/A
Profitability
6 /100
Weak
Net margin 362,386.00%
Op. margin 127,821.00%
FCF margin 129,588.00%
Quality
0 /100
Poor
ROA 373.57%
Asset turnover 0.00x
ROIC 406.31%
Debt
0 /100
High
Int. coverage -24.47x
Current ratio 0.06x
Net debt/EBITDA N/A
Stability
44 /100
Moderate
Rev. volatility 34.46%
Profitable years 0
Beta 0.93x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ADTX
Online

About the company

Aditxt, Inc. (ADTX) is a biotechnology company specializing in the development of innovative therapeutic and diagnostic technologies in the fields of immunology and biomedicine. The company focuses on developing products that can enhance patients' immune systems and improve their health. Aditxt develops diagnostic tools that allow for precise monitoring of immune responses and patients' health status. With the growing emphasis on personalized medicine and advanced diagnostic technologies, Aditxt, Inc. has the potential for sustained growth. Aditxt, Inc. (ADTX) shares might be an interesting choice for investors seeking involvement in the biotechnology and innovative diagnostic therapies industry.

Sector

Healthcare

Industry

Biotechnology

CEO

Jeffrey Busch

Employees

26

Headquarters

Mountain View

Upcoming events

02 DEC

Earnings

Upcoming earnings report

67d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.